Revvity (RVTY) investor relations material

Executive summary

• Q3 pro forma revenue was $710M, with 7% organic growth; adjusted operating margin was 29.4% and adjusted EPS was $1.37, above expectations.

• Life Sciences led growth at 9% organically; improving pharma-biotech demand, early AI-related demand, and operational efficiencies supported results.

• Reported Q3 revenue was $728.9M, up 4% YoY; net income was $62.3M versus $46.7M, and diluted EPS was $0.56 versus $0.40.

• Pro forma results and FY26 guidance exclude China Immunodiagnostics, which is agreed for divestiture.

Financial highlights

• Pro forma revenue growth contributions were organic +7%, M&A +1%, and FX -1%; ACD/Labs contributed to growth.

• Pro forma adjusted operating margin was 29.4%, up 340 bps YoY; adjusted gross margin was 62.4%, up 280 bps.

• Pro forma adjusted EPS was $1.37, up 21% YoY; adjusted tax rate was 18.2% and adjusted net interest and other was $21M.

• Q3 free cash flow was $152M; YTD free cash flow was $451M, or 105% of adjusted net income.

• Reported Q3 operating income was $95.1M versus $81.9M; 9M cash from continuing operations was $484.5M.

Outlook and guidance

• FY26 pro forma revenue guidance is ~$2.86B, with total growth of ~6% and organic growth of ~5%, versus prior organic guidance of 4%-5%.

• FY26 growth guidance includes FX +0.5% and M&A +0.75%; pro forma adjusted operating margin is ~28.8%, 80 bps above the start-of-year outlook.

• FY26 pro forma adjusted EPS guidance is $5.40-$5.45; assumptions include an ~18% adjusted tax rate and ~112M diluted shares.

• Q4 outlook includes ~5% organic growth, revenue midpoint of ~$755M, adjusted operating margin slightly above 32%, and pro forma adjusted EPS midpoint of $1.60; no buybacks assumed.